Cancer Archives

News and Trends 23 Sep 2015

NovoCure, the Israeli tumor specialist announces NASDAQ €170M IPO

NovoCure, originally from Haifa (Israel) is planning an IPO on NASDAQ with a target of €170M to make from its 12.5M shares on offer. It is hoped this financial injection will further commercialize its FDA-approved tumor treating field (TTField) medical device Optune. NovoCure is a commercial stage oncology biotech specialising in trials for solid-tumor treatments. Founded […]

September 23, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 9 Sep 2015

Encouraging results from Tedopi Phase II trials in patients with brain metastases

French Immuno-oncology Biotech OSE Pharma has announced its phase II results for Tedopi trials showing outcome for patients with brain metastases. Announced at the World Conference on Lung Cancer in Denver (US), OSE Pharma revealed how Tedopi had shown interesting results in patients diagnosed with brain metastases from advanced non-small cell lung cancer. Advanced non-small […]

September 9, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 8 Sep 2015

The First Biosimilar reached the US market… and it’s from Novartis

Biosimilar or copies of biological drugs are arriving on the market. After Europe, US gets its first Biosimilar too. The drug is produced by Novartis generic subsidiary, Sandoz and it will compete with Amgen‘s blockbuster drug Neupogen. When a drug generates $1.2Bn of annual revenues and its patent has expired, which company on earth wouldn’t be […]

September 8, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 8 Sep 2015

Wasp venom kills Cancer cells

Side effects of cancer treatments are almost as feared as the disease itself. But what if we could selectively destroy cancer cells without harming normal cells? Wasp venom might hold the secret to this largely awaited solution, as researchers from São Paulo State University and University of Leeds unraveled the mechanism of its cancer-targeting toxin. […]

September 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 7 Sep 2015

A Slice of Europe: MD Anderson looks to invest in EU Immuno-Oncology

MD Anderson is expanding its Immatics sharehold to spawn new Houston-based subsidiary Immatics US through investing into a $60M (€54M) pot. Also partnering up with French CAR-T pioneers Cellectis, and collaborating with German Merck, MD Anderson is seemingly wanting to immerse itself in the European immuno-oncology field. As a shareholder in the German cancer immunotherapy […]

September 7, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 4 Sep 2015

CAR-T therapy first clinical proof: Patient lives cancer-free 5 years on

A pioneering CAR-T cell therapy study from Novartis and the University of Pennsylvania demonstrates the impressive potential of the next-generation therapy. Five years after the start of the study, three patients have achieved complete remission and remain cancer-free. Here it is, the proof that the hype about CAR-T cell therapy was no hollow promise. Penn’s […]

September 4, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 3 Sep 2015

Adaptimmune Clinical Trials full-steam ahead with GSK investment!

Adaptimmune has had exciting results regarding the ongoing battle with Synovial Sarcoma. GSK looks to further invest in the expansion of the clinical trial to include two further cohorts. Adaptimmune, with a research base in Oxford (UK) and clinical base in Philadelphia (US), has overcome a milestone in their first cohort for clinical stage I/II T-cell therapy. They […]

September 3, 2015 - 3 minutesmins - By Dani Bancroft

future biomarkers immuno oncology lymphocytes

News and Trends 31 Aug 2015

Review: The Future of Biomarkers in Immuno-Oncology

Immuno-oncology is a Biotech field that is more than just hype – it could solve one of humanity’s biggest health challenges: Cancer. In order to bring more effective treatments with fewer side-effects, Biomarkers will play a key role. I wanted to get an expert view on the subject, so I called Bernhard Sixt, CEO of the […]

August 31, 2015 - 5 minutesmins - By Philip Hemme

News and Trends 27 Aug 2015

Dutch Immuno-Oncology company raises Massive Series C Financing round

Sofinnova Ventures and Novo A/S step into one of the biggest European series C financing rounds, which is about €72.8 million. The money goes to the Dutch immuno-oncology company Merus and will advance its cancer-fighting bispecific antibodies. Back in April, Merus announced its intention to go public at the Nasdaq, with the goal of raising […]

August 27, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 27 Aug 2015

Dutch Startup receives €2.5M from Europe to Block Cancer’s Spreading

The Eurostars program supports the Dutch start-up Oncodrone with fresh money to bring its metastasis-blocking drug towards clinical trials. Even with a promising technology, it’s not easy to succeed in the biotech field. The Eurostars program helps small companies through the tough starting phase. This year, the 2013 founded biotech start-up Oncodrone gets a 2.5 […]

August 27, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 25 Aug 2015

Leading German Biotechs MorphoSys and Immatics partner to pump up their Immuno-Oncology Therapies

Two German biotechs with highly successful platforms join forces to fight cancer. MorphoSys and Immatics Biotechnologies want to generate novel antibody-based therapeutics against multiple cancer antigens. They are two of the thriving forces in the German biotech scene. Munich’s MorphoSys claims having developed the most successful antibody library technology in the pharma industry, currently has 100 […]

August 25, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 18 Aug 2015

New mAb-treatment Improves the Life of European Children with Neuroblastoma

The European Commission granted marketing authorisation for United Therapeutics‘ Unituxin for the treatment of neuroblastoma in patients aged 12 months to 17 years. In Europe, approximately 1500 patients are diagnosed with neuroblastoma, the most common cancer in children. Some patients – the low-risk and intermediate risk group – are favored by an excellent prognosis with cure rates […]

August 18, 2015 - 2 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

NovoCure, the Israeli tumor specialist announces NASDAQ €170M IPO

Encouraging results from Tedopi Phase II trials in patients with brain metastases

The First Biosimilar reached the US market… and it’s from Novartis

Wasp venom kills Cancer cells

A Slice of Europe: MD Anderson looks to invest in EU Immuno-Oncology

CAR-T therapy first clinical proof: Patient lives cancer-free 5 years on

Adaptimmune Clinical Trials full-steam ahead with GSK investment!

Review: The Future of Biomarkers in Immuno-Oncology

Dutch Immuno-Oncology company raises Massive Series C Financing round

Dutch Startup receives €2.5M from Europe to Block Cancer’s Spreading

Leading German Biotechs MorphoSys and Immatics partner to pump up their Immuno-Oncology Therapies

New mAb-treatment Improves the Life of European Children with Neuroblastoma

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!